JP2022505158A5 - - Google Patents
Info
- Publication number
- JP2022505158A5 JP2022505158A5 JP2021521098A JP2021521098A JP2022505158A5 JP 2022505158 A5 JP2022505158 A5 JP 2022505158A5 JP 2021521098 A JP2021521098 A JP 2021521098A JP 2021521098 A JP2021521098 A JP 2021521098A JP 2022505158 A5 JP2022505158 A5 JP 2022505158A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- compound according
- domain
- target
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862747983P | 2018-10-19 | 2018-10-19 | |
| US62/747,983 | 2018-10-19 | ||
| PCT/US2019/056777 WO2020081841A1 (en) | 2018-10-19 | 2019-10-17 | Nk engager molecules and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022505158A JP2022505158A (ja) | 2022-01-14 |
| JP2022505158A5 true JP2022505158A5 (enExample) | 2022-10-19 |
| JP7453971B2 JP7453971B2 (ja) | 2024-03-21 |
Family
ID=70284811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021521098A Active JP7453971B2 (ja) | 2018-10-19 | 2019-10-17 | Ｎｋエンゲージャー分子およびその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12319737B2 (enExample) |
| EP (1) | EP3867278A4 (enExample) |
| JP (1) | JP7453971B2 (enExample) |
| KR (1) | KR102897353B1 (enExample) |
| CN (2) | CN112912400B (enExample) |
| AU (1) | AU2019361096A1 (enExample) |
| CA (1) | CA3114707A1 (enExample) |
| IL (1) | IL282193B2 (enExample) |
| WO (1) | WO2020081841A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| KR20240067088A (ko) * | 2021-09-16 | 2024-05-16 | 지티 바이오파마, 인크. | 융합 단백질을 표적으로 하는 pd-l1 및 이의 사용 방법 |
| CN117482246B (zh) * | 2022-12-30 | 2024-10-15 | 英百瑞(杭州)生物医药有限公司 | 抗cd33/cll1双特异性抗体-自然杀伤细胞偶联物及其用途 |
| JPWO2024248037A1 (enExample) * | 2023-05-30 | 2024-12-05 | ||
| WO2025136820A1 (en) * | 2023-12-18 | 2025-06-26 | Regents Of The University Of Minnesota | Poly-antigen cytokine-receptor complexes (paccs), compositions, and methods of use |
| WO2025223505A1 (zh) * | 2024-04-24 | 2025-10-30 | 南京吉盛澳玛生物医药有限公司 | 先天免疫超级连接器与完全免疫抗体的设计、制备及应用 |
| CN118325927A (zh) * | 2024-06-13 | 2024-07-12 | 广州安捷生物医学技术有限公司 | 编码nk细胞衔接器和car的多核苷酸及包含其的修饰细胞 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2511013A1 (en) | 2002-12-20 | 2004-07-15 | Biogen Idec Ma Inc. | Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof |
| WO2004058183A2 (en) | 2002-12-20 | 2004-07-15 | Biogen Idec Ma Inc. | Lymphotoxin beta receptor agents in combination with chemotherapeutic agents |
| EP2322547A1 (en) | 2003-06-25 | 2011-05-18 | Crucell Holland B.V. | Myeloid cell-specific lectin |
| HRP20170342T1 (hr) | 2003-07-24 | 2017-05-19 | Innate Pharma S.A. | Metode i sastavi za povećanje učinkovitosti terapijskih protutijela koristeći tvari koje potenciraju nk stanice |
| KR100773259B1 (ko) | 2004-03-19 | 2007-11-05 | 모리나가 뉴교 가부시키가이샤 | 암치료를 위한 약제 |
| EP1861425B1 (en) | 2005-03-10 | 2012-05-16 | Morphotek, Inc. | Anti-mesothelin antibodies |
| US8993295B2 (en) | 2006-07-20 | 2015-03-31 | The General Hospital Corporation | Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting |
| ATE535805T1 (de) | 2007-01-26 | 2011-12-15 | Univ Louisville Res Found | Verfahren zur erkennung von autoantikörpern zur diagnostizierung und charakterisierung von erkrankungen |
| EP2014680A1 (en) * | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
| EP2197909A4 (en) | 2007-08-24 | 2014-12-03 | Univ Minnesota | REAGENTS ON RECIPES |
| EP2332994A1 (en) | 2009-12-09 | 2011-06-15 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Trispecific therapeutics against acute myeloid leukaemia |
| UY33492A (es) | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| WO2012017522A1 (ja) | 2010-08-03 | 2012-02-09 | 富士通株式会社 | 検証プログラムおよび検証装置 |
| US8507222B2 (en) | 2010-09-21 | 2013-08-13 | Altor Bioscience Corporation | Multimeric IL-15 soluble fusion molecules and methods of making and using same |
| CN102251013A (zh) | 2011-02-22 | 2011-11-23 | 北京市肿瘤防治研究所 | 一个识别肿瘤起始细胞的抗体和抗原及其应用 |
| CN103732623B (zh) | 2011-06-03 | 2017-09-29 | 佐马技术有限公司 | 对TGF‑β具有特异性的抗体 |
| EP2537933A1 (en) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
| WO2013039883A1 (en) | 2011-09-12 | 2013-03-21 | Abbvie Biotherapeutics Inc. | Artificial nk cells and uses thereof |
| WO2013163427A1 (en) | 2012-04-25 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antibodies to treat hiv-1 infection |
| HUE042040T2 (hu) | 2012-09-27 | 2019-06-28 | Merus Nv | Bispecifikus IGG antitestek mint T-sejt kapcsolók |
| WO2014138306A1 (en) | 2013-03-05 | 2014-09-12 | Baylor College Of Medicine | Engager cells for immunotherapy |
| US9879081B2 (en) | 2013-06-25 | 2018-01-30 | Samsung Electronics Co., Ltd. | Protein complex, bispecific antibody including the protein complex, and method of preparation thereof |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| US20170335281A1 (en) * | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| SG10201913782UA (en) | 2014-07-21 | 2020-03-30 | Novartis Ag | Treatment of cancer using a cll-1 chimeric antigen receptor |
| JP6797803B2 (ja) | 2014-12-31 | 2020-12-09 | セルジーン コーポレイション | ナチュラルキラー細胞を用いて血液障害、固形腫瘍、又は感染性疾患を治療する方法 |
| US10501545B2 (en) | 2015-06-16 | 2019-12-10 | Genentech, Inc. | Anti-CLL-1 antibodies and methods of use |
| MX389194B (es) | 2015-10-06 | 2025-03-20 | Univ Minnesota | Compuestos terapéuticos y métodos. |
| MA55746A (fr) | 2016-01-21 | 2022-03-02 | Novartis Ag | Molécules multispécifiques ciblant cll-1 |
| CA3055200A1 (en) * | 2017-03-03 | 2018-09-07 | Obsidian Therapeutics, Inc. | Compositions and methods for immunotherapy |
| EA202090718A1 (ru) * | 2017-09-14 | 2020-07-01 | Драгонфлай Терапьютикс, Инк. | Белки, связывающие nkg2d, cd16 и лектиноподобную молекулу-1 c-типа (cll-1) |
| WO2019246593A2 (en) * | 2018-06-22 | 2019-12-26 | Fred Hutchinson Cancer Research Center | Compositions and methods to target cll-1 and cd123 for the treatment of acute myeloid leukemia and related disorders |
-
2019
- 2019-10-17 CN CN201980067595.3A patent/CN112912400B/zh active Active
- 2019-10-17 US US17/285,447 patent/US12319737B2/en active Active
- 2019-10-17 IL IL282193A patent/IL282193B2/en unknown
- 2019-10-17 WO PCT/US2019/056777 patent/WO2020081841A1/en not_active Ceased
- 2019-10-17 KR KR1020217011728A patent/KR102897353B1/ko active Active
- 2019-10-17 JP JP2021521098A patent/JP7453971B2/ja active Active
- 2019-10-17 CA CA3114707A patent/CA3114707A1/en active Pending
- 2019-10-17 EP EP19873982.3A patent/EP3867278A4/en active Pending
- 2019-10-17 AU AU2019361096A patent/AU2019361096A1/en active Pending
- 2019-10-17 CN CN202510655674.3A patent/CN120535653A/zh active Pending
-
2025
- 2025-04-29 US US19/193,669 patent/US20250304701A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022505158A5 (enExample) | ||
| JP7716299B2 (ja) | 小細胞肺癌に対する標的療法 | |
| US20250250342A2 (en) | Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof | |
| Xia et al. | Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities | |
| ES2719495T5 (en) | Anti-b7-h6 antibody, fusion proteins, and methods of using the same | |
| RU2012137503A (ru) | Лекарственный препарат для лечения и/или профилактики рака | |
| RU2018116565A (ru) | Терапевтические соединения и способы | |
| US12168695B2 (en) | Bispecific antibody for cancer immunotherapy | |
| HK1259190A1 (zh) | 嵌合抗原受体相关的方法和组合物 | |
| JP2009505676A5 (enExample) | ||
| RS63965B1 (sr) | Vegf/dll4 vеzujući agensi i njihova upotreba | |
| UA121914C2 (uk) | Молекула, що зв'язує pd1 і lag3 | |
| JP2006500009A5 (enExample) | ||
| CN104768579A (zh) | 使用Wnt途径结合剂来治疗神经内分泌肿瘤的方法 | |
| JP2010535713A5 (enExample) | ||
| SI2342234T1 (en) | MONOCOLIC ANTI-GT468 CANCER CANCER PROTITEL | |
| KR20150018604A (ko) | 히포 경로를 조절하는 결합제 및 그의 용도 | |
| RU2014141151A (ru) | Диагностика и лечение злокачественной опухоли с использованием антитела против ereg | |
| JP2018510881A5 (enExample) | ||
| JP2022548145A5 (enExample) | ||
| RS65666B1 (sr) | Glipikan 2 kao tumor marker i terapijski cilj | |
| WO2023031644A1 (en) | Anti-fibroblast activation protein (fap) single domain antibodies and uses thereof | |
| CN118290584A (zh) | 一种包括nk细胞的药物组合物及其在制备治疗肿瘤药物中的应用 | |
| CN117003897A (zh) | 靶向Claudin18.2的CAR-T细胞及其用途 | |
| Mendelsohn | Jeremiah Metzger Lecture. Targeted cancer therapy |